Auven Therapeutics Management LLLP, of St. Thomas, U.S. Virgin Islands, said it executed agreements to sell 100 percent of Ocular Technologies Sarl, a wholly owned subsidiary through which all rights to Seciera (OTX-101) are held, to a subsidiary of Sun Pharmaceuticals Industries Ltd., of Mumbai, India. Read More

Ritter Pharmaceuticals Inc., of Los Angeles, said it priced an underwritten public offering of 2.12 million shares of its common stock at $2.35 each. Read More

Eurocrine Vaccines AB, of Solna, Sweden, said it started a phase I/II trial of its quadrivalent influenza vaccine, Immunose Flu, a nose-drop formulation based on the company's Endocine technology and inactivated split antigens. Read More

Biogen Inc., of Cambridge, Mass., reported total revenues of $3 billion in the third quarter of 2016 financial results, a 6 percent increase over the same quarter in the prior year. Read More

The city of Chicago has amended its complaint against several biopharma companies, alleging that their marketing of prescription opioids for chronic pain violated local and state law while opening "the floodgates of opioid use and abuse" and spurring a resurgence in heroin use. Read More

DUBLIN – Evotec AG is committing about half of its cash resources to acquire Cyprotex plc in an all-cash deal valued at £55.36 million ($67.5 million), which will add a high-throughput ADME-Tox platform to its preclinical drug discovery research service offerings. Read More

As gene editing of blood stem cells is progressing toward clinical application, one question has been how to make the technology simple and cheap enough to make it a realistic option for the large numbers of patients who could potentially benefit. Read More

SUZHOU, China – Ruyi He, chief scientist of the CFDA and the Centre for Drug Evaluation (CDE), outlined the government's commitment to streamline and speed up the review process for innovative drugs, sharing support for more dynamic communication between reviewers and sponsors. Read More

Third-quarter results from Vertex Pharmaceuticals Inc. didn't much rattle Wall Street, but some onlookers made known their uncertainty about the company's plan to start two phase II studies with next-generation correctors VX-440 and VX-152 in triple combination regimens with tezacaftor (VX-661) and Vertex's Kalydeco (ivacaftor) in cystic fibrosis (CF). Read More

Oncogenex Pharmaceuticals Inc. reported that a combination of its lead anticancer candidate apatorsen and the chemotherapy docetaxel met the primary endpoint of overall survival in the investigator-sponsored phase II Borealis-2 trial, reducing the risk of death for metastatic bladder cancer patients who failed initial therapy by 20 percent vs. treatment with docetaxel alone (hazard ratio (HR) of 0.80, 95 percent confidence interval: 0.65-0.98; p = 0.078). Read More

Medical technology may have scored just as many hits on the Cleveland Clinic's 2017 Top 10 list of medical innovations, but biopharma won the race to the top, taking the top four spots among breakthroughs expected in the coming year. Read More